Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Nebraska for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Nebraska only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Nebraska (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Yungpo Su (NPI 1457322166)

Field	Value
Entity Type	Individual
Organization	Yungpo Su
Address	7500 Mercy Rd
City	Omaha
State	NE
ZIP	68124
Taxonomy	Hematology & Oncology Physician
NPI Enumerated	January 30, 2006

Payer Source	Total Paid
Medicare	$1.9M
Medicaid	$0

Key Findings

This provider’s Medicare footprint is concentrated but meaningful: Total Medicare revenue is $1.9M while Total Medicaid revenue is none (no Medicaid billing on file), making this effectively a single-payer Medicare practice from the claims on file. The lack of Medicaid activity suggests limited engagement with the Medicaid population and means payer negotiations and utilization patterns will be driven almost entirely by Medicare dynamics.

Revenue is highly concentrated in a very small set of drugs and services: the precomputed top 3 Medicare codes by revenue account for 91.9% of this provider's total Medicare revenue, with J9271 at $928.8K (48.6%), J9299 at $764.2K (39.9%), and 99214 at $64.3K (3.4%). That concentration indicates the practice’s financial performance is heavily dependent on two high-cost oncology injections plus routine E/M visits.

The code mix points to an infusion-based hematology/oncology practice focused on immune checkpoint inhibitors and outpatient chemotherapy administration: J9271 (pembrolizumab) and J9299 (nivolumab) are the top revenue drivers, and chemotherapy administration codes such as 96413 (395 claims, $37.5K revenue, 2.0%) and add-on infusion codes (96417, 96415) also appear in the top codes. Together these codes imply the provider operates an office/clinic infusion service where systemic cancer therapies are a core service line.

Competitive standing for the two highest-revenue drugs is mixed: J9299 ranks #63 of 505 providers nationally (88th percentile; typical, unremarkable volume), indicating an above-typical national presence for nivolumab administration, while J9271 ranks #320 of 1841 providers nationally (82th percentile; typical, unremarkable volume), which is solid but not dominant for pembrolizumab. These rank/percentile positions suggest the provider is a notable regional participant for immune checkpoint inhibitors but not an extreme national outlier.

Office visit (E/M) activity is above typical peer volume: 99214 shows 707 claims and $64.3K revenue (3.4% of Medicare revenue) and ranks #25666 of 479517 providers nationally (95th percentile; notably above typical national volume). This elevated E/M percentile implies sustained ambulatory follow-up and management activity that complements the infusion services rather than being purely procedural.

Several infusion-support codes and adjunctive medications appear at typical or below-peer levels: for example, 96413 ranks #1162 of 7514 providers (84th percentile; typical, unremarkable volume) and J0897 (denosumab) generates $25.9K (1.4%) but ranks in the 23th percentile. These patterns show that while high-cost checkpoint inhibitors dominate revenue, supportive oncology and administration codes are present at more ordinary volumes.

There are a few low-percentile entries among the top codes that may reflect product- or documentation-specific patterns rather than broad service expansion: J1439 (ferric carboxymaltose) appears with $10.5K revenue (0.5%) but ranks #1161 of 1209 providers nationally (3th percentile; typical, unremarkable volume). Such low-ranked supportive therapy billing contrasts with the high relative standing for core oncology drugs and underscores the narrow revenue base.

The provider is long-tenured in Medicare enrollment, with NPI enumerated 2006-01-30 (~20 years ago), which supports continuity of care and an established referral/administrative footprint; combined with the heavy Medicare-only billing profile, this tenure suggests an experienced outpatient oncology practice whose economics are driven by outpatient infusion of high-cost oncology biologics.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

44 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J9271	Injection, pembrolizumab, 1 mg	21,600	$40	$928.8K
J9299	Injection, nivolumab, 1 mg	31,840	$20	$764.2K
99214	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the…	710	$90	$64.3K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	400	$100	$37.5K
J0897	Injection, denosumab, 1 mg	1,440	$20	$25.9K
99215	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a high level of medical decision making, and/or the…	150	$130	$20.3K
J1439	Injection, ferric carboxymaltose, 1 mg	10,500	$1	$10.5K
99205	The provider sees a new patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a high level of medical decision making, and/or the provider…	40	$160	$7.1K
99213	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a low level of medical decision making, and/or the…	120	$50	$6.4K
99223	The provider sees a patient for an initial hospital inpatient or observation care visit involving evaluation and management (E/M). The visit involves a high level of medical decision making or the…	40	$130	$5.5K

Showing 1–10 of 44

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 44 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Nebraska Distribution

Yungpo Su — 2 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Nebraska

Full comparison — all codes billed, vs. state median

44 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J9271	6	30	14,400	$40	$671.6K
J9299	1	10	19,300	$20	$444.5K
J0897	148	200	2,040	$20	$62.7K
J1439	30	30	25,880	$1	$26.4K
96413	15	80	60	$90	$18.2K
99214	187	3,210	110	$70	$14.9K
99233	584	830	80	$90	$11.7K
J3490	2	30	60	$160	$11.3K
99232	696	1,390	80	$60	$8.6K
99213	1,276	3,220	90	$50	$7.9K

Showing 1–10 of 44

Related Providers

Other providers that share a Tax Identification Number (TIN) with Yungpo Su, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Stefano Tarantolo	NE	Hematology & Oncology Physician	$3.2M	$0
Samuel Mehr	NE	Nuclear Medicine Physician	$2.5M	$0
Ralph Hauke	NE	Hematology & Oncology Physician	$2.5M	$0
Gamini Sooriyaarachchi	FL	Medical Oncology Physician	$2.2M	$0
Ryan Ramaekers	NE	Hematology & Oncology Physician	$2.1M	$0
Joel Michalski	NE	Internal Medicine Physician	$2M	$0
Margaret Block	NE	Hematology & Oncology Physician	$1.7M	$0
Robert Langdon	NE	Hematology & Oncology Physician	$1.4M	$0
Muhammad Haroon	NE	Hematology & Oncology Physician	$1.4M	$0
Timothy Dorius	NE	Internal Medicine Physician	$1M	$0

Nearby Providers

Other providers in the same ZIP code as Yungpo Su, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Alegent Health Bergan Mercy Health System	NE	General Acute Care Hospital	$0	$45.8M
Alegent Creighton Clinic	NE	Family Medicine Physician	$0	$43.2M
Childrens Home Healthcare	NE	Home Health Agency	$0	$40M
Maxim Healthcare Services, Inc.	NE	Home Health Agency	$0	$29.7M
Lutheran Family Services Of Ne, Inc	NE	Mental Health Counselor	$0	$5.8M
Epn Of Nebraska LLC	NE	Emergency Medicine Physician	$0	$5.6M
Pediatric Dental Specialists Of Greater Nebraska - Omaha, LLC	NE	Pediatric Dentistry	$0	$2.5M
Osc LLC	NE	Ambulatory Surgical Clinic/Center	$1.3M	$799.9K
Shoptikal LLC	NE	Eyewear Supplier	$0	$1.9M
House Enterprises Inc	NE	Emotionally Disturbed Childrens' Residential Treatment Facility	$0	$1.8M

Yungpo Su — Billing Profile & Reimbursement Data

Sign up for Yungpo Su — Billing Profile & Reimbursement Data policy alerts

Yungpo Su — Billing Profile & Reimbursement Data

Sign up for Yungpo Su — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References